Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Quest Diagnostics (DGX)

Quest Diagnostics Q2 revenue rises 15.2% to $2.76 billion; raises 2025 guidance

Positive Impact 4 of 5 earnings Written later

Quest Diagnostics reported second-quarter 2025 revenue of $2.76 billion, up 15.2% from a year earlier, and reported diluted EPS of $2.47, up 21.7%. The company raised its adjusted full-year 2025 EPS outlook to $9.63-$9.83 and its net revenue outlook to $10.80 billion-$10.92 billion, but narrowed its reported EPS outlook to $8.60-$8.80, which is lower than the prior $8.62-$8.87 range.

Key points

  • Q2 2025 net revenues $2.76 billion, up 15.2%; organic revenues grew 5.2%, per the CEO's statement
  • Q2 diluted EPS $2.47 vs. $2.03 a year earlier; adjusted diluted EPS $2.62 vs. $2.35
  • Full-year 2025 adjusted diluted EPS raised to $9.63-$9.83 from $9.55-$9.80; reported diluted EPS lowered to $8.60-$8.80 from $8.62-$8.87
  • Year-to-date cash from operations $858 million, up 67.1%

The filing

CompanyQuest Diagnostics (DGX)
Form8-K, current report
Filed with the SECJul 22, 2025, 6:48 AM ET
Accession number0001022079-25-000172

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.